Drug intelligence / Profile preview

IPF-2142

Development stage: Preclinical
Lead developer: iPHARMA
Modality: Small Molecules

Overview

IPF-2142 is a preclinical asset developed by iPharma, a Luxembourg-based precision medicine company. It functions as a TOP2 inhibitor and is being developed for the treatment of cancer. BioLineRx has made a strategic minority investment in iPharma, granting BioLineRx a first right of refusal or co-development options on select iPharma programs, including IPF-2142.

Targets

TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on IPF-2142.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPF-2142.

Explore the full profile